Aurinia (AUPH) COO receives stock grants and settles taxes with shares

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. Chief Operating Officer Matthew Maxwell Donley reported equity compensation and related tax withholding transactions. On February 27, 2026, he received a grant of 97,256 employee stock options at an exercise price of $0.00 per share and a grant of 58,160 shares of common stock at no cost, both held directly.

Following the stock award, his directly held common stock position increased to 721,060 shares. On March 2, 2026, 40,761 common shares valued at $14.21 per share were disposed of through a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving 680,299 common shares held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donley Matthew Maxwell

(Last) (First) (Middle)

#140, 14315-118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		58,160(1)	A	$0	721,060	D
Common Stock	03/02/2026		F		40,761(2)	D	$14.21	680,299	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.97	02/27/2026		A		97,256		(3)	02/27/2036	Common Stock	97,256	$0	97,256	D

Explanation of Responses:

1. Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

2. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

3. One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Remarks:

	/s/ Matthew Maxwell Donley	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AUPH COO Matthew Maxwell Donley report?

He reported a grant of 97,256 stock options and 58,160 common shares, plus a 40,761-share tax-withholding disposition. These moves reflect routine equity compensation and tax settlement rather than open-market buying or selling activity.

How many Aurinia Pharmaceuticals (AUPH) shares does the COO hold after these transactions?

After the reported transactions, Matthew Maxwell Donley directly holds 680,299 shares of Aurinia Pharmaceuticals common stock. This figure reflects equity grants received and shares withheld for taxes upon vesting of restricted stock units.

Was the 40,761-share AUPH disposition an open-market sale?

No. The 40,761-share disposition was for tax withholding at $14.21 per share, satisfying tax obligations upon vesting of restricted stock units. It was not reported as an open-market sale transaction by the Chief Operating Officer.

What were the terms of the 97,256 Aurinia Pharmaceuticals stock options granted?

The grant covered 97,256 employee stock options at an exercise price of $0.00 per share. One-third vests twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments thereafter, subject to continued conditions.

What equity award of Aurinia Pharmaceuticals common stock did the COO receive?

He received a grant of 58,160 shares of Aurinia Pharmaceuticals common stock at no cost on February 27, 2026. These shares increased his directly held common stock position before subsequent tax-withholding transactions reduced the balance.

How are performance rights and restricted stock units described for AUPH in this filing?

Each performance right represents a contingent right to receive one common share, vesting in four tranches at higher target prices with one-year retention per tranche. Some shares were withheld to satisfy tax obligations upon vesting of restricted stock units.